Broncodilatatore

A livello polmonare sono presenti recettori adrenergici β2 e recettori muscarinici M3. Queste proteine dimostrano effetti opposti sull'apparato respiratorio se stimolate dai legandi fisiologici (rispettivamente adrenalina e acetilcolina) o da opportune molecole di sintesi.
I recettori adrenergici vengono attivati dall'adrenalina rilasciata dalla midollare del surrene (non esiste, infatti, innervazione simpatica sui polmoni), determinando broncodilatazione e diminuzione delle secrezioni bronchiali.
I recettori colinergici, al contrario, rispondono agli stimoli del sistema parasimpatico inducendo broncocostrizione e aumentando le secrezioni.
Hanno azione adrenergica β2 anche derivati terpenici, quali il limonene, il pinene e l'eucaliptolo.
Si ricorda che, nonostante si parli di azione selettiva β2 a livello polmonare, alcuni di questi farmaci erano o sono usati per altri scopi, tra cui rilassare la muscolatura uterina ed inibire le contrazioni in caso di parto prematuro. (fonte: Wikipedia)
Novartis commends publication of major report which recommends broad use of dual bronchodilators to treat COPD  -  Novartis International AG / Novartis commends publication of major report which recommends broad use of dual bronchodilators to treat COPD . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for…
Global Orally Inhaled Bronchodilators Market to 2022  -  (http://www.researchandmarkets.com/research/v3tw68/orally_inhaled) has announced the addition of the "Orally Inhaled Bronchodilators to 2022" report to their offering. Asthma and COPD continue to be a health segments that present significant challenges to patients and the caregiver…
COPD Drug Market Opportunity and Clinical Pipeline Analysis  -  The global market for COPD has been estimated to be close to US$ 12 billion in 2013. With a high number of new and more efficient and convenient drugs crowding the market, it is expected that this market would grow at a CAGR of 8% to reach close to US$ 17.5 billion by 2018. Some of the…
Verona Pharma Plc ("Verona Pharma" Or The "Company") Peer-Reviewed Paper Suggests RPL554 With Glycopyrrolate, Or Other Muscarinic Receptor Antagonists, Produces Synergistic Bronchodilation  -  The paper suggests that inhibiting both PDE3 and 4 with RPL554 induces a larger relaxation of human bronchi than that produced by either a…
Novartis once-daily QVA149 shows superior efficacy in reducing exacerbations, improving lung function and quality of life in COPD patients  -  SPARK results published in Lancet Respiratory Medicine showed that dual bronchodilator QVA149 significantly reduced the rate of moderate or severe COPD exacerbations compared to glycopyrronium 50…
  • 1 (current)
  • 2
Loading....